HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
14.94
-0.51 (-3.30%)
Nov 7, 2025, 12:01 PM EST - Market open
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $277.68M in the half year ending June 30, 2025, a decrease of -47.89%. This brings the company's revenue in the last twelve months to $602.20M, down -1.41% year-over-year. In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%.
Revenue (ttm)
$602.20M
Revenue Growth
-1.41%
P/S Ratio
4.30
Revenue / Employee
$332,522
Employees
1,811
Market Cap
2.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HCM News
- 2 days ago - HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript - Seeking Alpha
- 4 days ago - HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - GlobeNewsWire
- 6 days ago - HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript - Seeking Alpha
- 24 days ago - HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - GlobeNewsWire
- 25 days ago - HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewsWire
- 5 weeks ago - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 - GlobeNewsWire